Citations

Clear

6273 citation(s) found for "To, Andrew".

Lung Epithelial Cell Line Immune Responses to Pneumocystis
Kottom, Theodore J. , Carmona, Eva M. , Carmona, Eva M , Kottom, Theodore J , Limper, Andrew H.

Mayo Clinic

Journal of Fungi | July 6, 2023 | Volume: 9 | Issue: 7 | Pages: 729

10.3390/jof9070729 | PMID 37504718 Get It

Pneumocystis sp. are fungal pathogens and members of the Ascomycota phylum. Immunocompetent individuals can readily eliminate the fungus, whereas immunocompromised individuals can develop Pneumocystis jirovecii pneumonia (PJP). Currently, over 500,000 cases occur worldwide, and the organism is listed on the recently released WHO fungal priority pathogens list. Overall, the number of PJP cases over the last few decades in developed countries with the use of highly effective antiretroviral therapy has decreased, but the cases of non-HIV individuals using immunosuppressive therapies have significantly increased. Even with relatively effective current anti-Pneumocystis therapies, the mortality rate remains 30–60% in non-HIV patients and 10–20% during initial episodes of PJP in HIV/AIDS patients. Although the role of alveolar macrophages is well studied and established, there is also well-established and emerging evidence regarding the role of epithelial cells in the immune response to fungi. This mini review provides a brief overview summarizing the innate immune response of the lung epithelium and various continuously cultured mammalian cell lines to Pneumocystis.
Cardiac Sarcoidosis Mimickers: Genetic Testing in Undifferentiated Inflammatory Cardiomyopathies
Castrichini, Matteo , Agboola, Kolade M. , Vyas, Hridyanshu , Ezzeddine, Omar F. Abou, Siontis, Konstantinos C. , Giudicessi, John R. , Rosenbaum, Andrew , Pereira, Naveen L. , AbouEzzeddine, Omar F. , Abou Ezzeddine, Omar F, Rosenbaum, Andrew N , Castrichini, Matteo , AbouEzzeddine, Omar F

Mayo Clinic

Circulation: Genomic and Precision Medicine | July 4, 2023 | Volume: 16 | Issue: 5 | Pages: 478-479

10.1161/circgen.123.004099 | PMID 37401491 Get It

Association of the CHEK2 c. 1100delC variant, radiotherapy, and systemic treatment with contralateral b
Morra, Anna , Schreurs, Maartje A. C. , Andrulis, Irene L. , Anton‐Culver, Hoda , Beckmann, Matthias W. , Bolla, Manjeet K. , Camp, Nicola J. , Cessna, Melissa H., Chang‐Claude, Jenny , Collaborators, NBCS, Dörk, Thilo , Easton, Douglas F. , Eccles, Diana M., Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Graßmann, Felix , Gündert, Melanie , Hahnen, Eric , Haiman, Christopher A. , Hamann, Ute, Harrington, Patricia, Hoppe, Reiner , Hopper, John L. , Houlston, Richard S. , Howell, Anthony, Investigators, ABCTB, Investigators, kConFab, Janni, Wolfgang, John, Esther M. , Johnson, Nichola , Jones, Michael E. , Kristensen, Vessela N. , Kurian, Allison W. , Lambrechts, Diether , Lindblom, Annika , Mannermaa, Arto, Mavroudis, Dimitrios, Muranen, Taru , Nevelsteen, Ines, Neven, Patrick , Newman, William G. , Obi, Nadia , Offit, Kenneth , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Peterlongo, Paolo , Phillips, Kelly‐Anne , Plaseska‐Karanfilska, Dijana , Rack, Brigitte , Rhenius, Valerie , Romero, Atocha , Sawyer, Elinor J. , Schmutzler, Rita K. , Schuetze, Sabine, Shah, Mitul , Smichkoska, Snezhana , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Vachon, Celine M. , Veen, Elke M. van , Wang, Qin , Wendt, Camilla, Wildiers, Hans , Pharoah, Paul D.P. , Adank, Muriel A. , Hooning, Maartje J. , Howell, Anthony , Ramus, Susan J. , Bojesen, Stig E. , Eccles, Diana , Cummings, Margaret C. , Loi, Sherene , Lambrechts, Diether , Howell, Sacha J. , Bojesen, Stig E , Dörk, Thilo , Figueroa, Jonine D , Gabrielson, Marike , Gago-Dominguez, Manuela , García-Sáenz, José A , Hahnen, Eric , Hartikainen, Jaana M , Jernström, Helena , John, Esther M , Lambrechts, Diether , Muranen, Taru A , Nevanlinna, H , Patel, Alpa V , Pylkäs, Katri , Rashid, Muhammad U , Hooning, Maartje J. , Lambrechts, Diether , Peterlongo, Paolo , Ramus, Susan J , Pharoah, Paul D P , Eccles, Diana , Houlston, Richard S , Anton-Culver, Hoda , Evans, D Gareth , Jones, Michael E , Newman, William G , Romero, Atocha , García-Closas, Montserrat , Kurian, Allison W , Loi, Sherene , Bojesen, Stig E , Phillips, Kelly-Anne , Wildiers, Hans , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Augustinsson, Annelie , Behrens, Sabine , Brauch, Hiltrud , Broeks, Annegien , Buys, Saundra S. , Castelao, Jose E. , Chung, Wendy K. , Collaborators, NBCS, Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Daly, Mary Beryl , Dennis, Joe , Devilee, Peter , Dunning, Alison M. , Dwek, Miriam , Eriksson, Mikael , Fehm, Tanja , Figueroa, Jonine D. , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Hartikainen, Jaana M. , Howell, Anthony, Investigators, ABCTB, Investigators, kConFab, Jakubowska, Anna , Jernström, Helena , Marchand, Loı̈c Le , Lubiński, Jan , Lux, Michael P. , Mannermaa, Arto, Mulligan, Anna Marie , Nevanlinna, Heli , Olshan, Andrew F. , Polley, Eric C. , Presneau, Nadège , Pylkäs, Katri , Radice, Paolo , Rashid, Muhammad Usman , Robson, Mark E. , Saloustros, Emmanouil , Scott, Christopher G. , Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Tomczyk, Katarzyna , Troester, Melissa A. , Vachon, Celine M. , Winqvist, Robert , Ziogas, Argyrios , Hall, Per N , Hollestelle, Antoinette , Schmidt, Marjanka K.

Mayo Clinic

Cancer Medicine | July 4, 2023 | Volume: 12 | Issue: 15 | Pages: 16142-16162

10.1002/cam4.6272 | PMID 37401034 Get It

Abstract Background Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC‐specific survival (BCSS) compared to non‐carriers. Aim To assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Methods Analyses were based on 82,701 women diagnosed with a first primary invasive BC including 963 CHEK2 c.1100delC carriers; median follow‐up was 9.1 years. Differential associations with treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi‐state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. Results There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status. The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR (95% CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi‐state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non‐carriers also after accounting for CBC occurrence [HR (95% CI): 1.30 (1.09–1.56)]. Conclusion Systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.
Optimizing single cell proteomics using trapped ion mobility spectrometry for label-free experiments
Mun, Dong‐Gi , Bhat, Firdous Ahmad , Ding, Husheng, Natesampillai, Sekar, Johnson, Kenneth L. , Pandey, Akhilesh , Bhat, Firdous A., Pandey, Akhilesh , Mun, Dong-Gi , Madden, Benjamin J. , Badley, Andrew D. , Kelly, Ryan T

Mayo Clinic

The Analyst | July 3, 2023 | Volume: 148 | Issue: 15 | Pages: 3466-3475

10.1039/d3an00080j | PMID 37395315 Get It

We present optimized settings for ramp times and ion mobility range in trapped ion mobility spectrometry experiments involving single cell analysis.
Cerebrospinal Fluid Biomarkers for Diagnosis and the Prognostication of Acute Ischemic Stroke: A Systematic Review
Adeleye, Olufunmilola , Winkler, Ethan A. , Hartke, Joelle N., Karahalios, Katherine , Mihaljević, Sandra, Rani, Anupama , Raikwar, Sudhanshu P. , Rulney, Jarrod, Scherschinski, Lea , Ducruet, Andrew F. , Albuquerque, Felipe C. , Lawton, Michael T. , Raikwar, Sudhanshu , Scherschinski, Lea , Adeleye, Olufunmilola , Naik, Anant , Koester, Stefan Wolfgang , Desai, Shashvat M. , Catapano, Joshua S , Jadhav, Ashutosh P. , Jha, Ruchira Menka

Mayo Clinic

International Journal of Molecular Sciences | June 30, 2023 | Volume: 24 | Issue: 13 | Pages: 10902

10.3390/ijms241310902 | PMID 37446092 Get It

Despite the high incidence and burden of stroke, biological biomarkers are not used routinely in clinical practice to diagnose, determine progression, or prognosticate outcomes of acute ischemic stroke (AIS). Because of its direct interface with neural tissue, cerebrospinal fluid (CSF) is a potentially valuable source for biomarker development. This systematic review was conducted using three databases. All trials investigating clinical and preclinical models for CSF biomarkers for AIS diagnosis, prognostication, and severity grading were included, yielding 22 human trials and five animal studies for analysis. In total, 21 biomarkers and other multiomic proteomic markers were identified. S100B, inflammatory markers (including tumor necrosis factor-alpha and interleukin 6), and free fatty acids were the most frequently studied biomarkers. The review showed that CSF is an effective medium for biomarker acquisition for AIS. Although CSF is not routinely clinically obtained, a potential benefit of CSF studies is identifying valuable biomarkers from the pathophysiologic microenvironment that ultimately inform optimization of targeted low-abundance assays from peripheral biofluid samples (e.g., plasma). Several important catabolic and anabolic markers can serve as effective measures of diagnosis, etiology identification, prognostication, and severity grading. Trials with large cohorts studying the efficacy of biomarkers in altering clinical management are still needed.
Normothermic Machine Perfusion of Donor Livers for Transplantation in the United States
Chapman, William C. , Barbas, Andrew S. , D’Alessandro, Anthony M. , Vianna, Rodrigo , Abt, Peter L. , Sonnenday, Christopher J. , Barth, Rolf N. , Alvarez-Casas, Josue, Yersiz, Hasan, Genyk, Yuri , Sher, Linda , Singer, Andrew L., Doyle, Maria B. Majella, Sudan, Debra L. , Al‐Adra, David , Khan, Adeel , Subramanian, Vijay , Abraham, Nader , Olthoff, Kim M. , Tekin, Akin , Berg, Lynn, Morris, C.G. , Randle, Lucy V., Friend, Peter J. , Singer, Andrew, Chapman, William C , Sudan, Debra L , Kubal, Chandrashekhar A. , Eckhoff, Devin E. , Cannon, Robert M. , Feng, Sandy , Roll, Garrett Richard , Cohen, Ari J. , Coussios, Constantin C. , Knechtle, Stuart J.

Mayo Clinic

Annals of Surgery | June 30, 2023 | Volume: 278 | Issue: 5 | Pages: e912-e921

10.1097/sla.0000000000005934 | PMID 37389552 Get It

Objective: To compare conventional low-temperature storage of transplant donor livers [static cold storage (SCS)] with storage of the organs at physiological body temperature [normothermic machine perfusion (NMP)]. Background: The high success rate of liver transplantation is constrained by the shortage of transplantable organs (eg, waiting list mortality >20% in many centers). NMP maintains the liver in a functioning state to improve preservation quality and enable testing of the organ before transplantation. This is of greatest potential value with organs from brain-dead donor organs (DBD) with risk factors (age and comorbidities), and those from donors declared dead by cardiovascular criteria (donation after circulatory death). Methods: Three hundred eighty-three donor organs were randomized by 15 US liver transplant centers to undergo NMP (n = 192) or SCS (n = 191). Two hundred sixty-six donor livers proceeded to transplantation (NMP: n = 136; SCS: n = 130). The primary endpoint of the study was “early allograft dysfunction” (EAD), a marker of early posttransplant liver injury and function. Results: The difference in the incidence of EAD did not achieve significance, with 20.6% (NMP) versus 23.7% (SCS). Using exploratory, “as-treated” rather than “intent-to-treat,” subgroup analyses, there was a greater effect size in donation after circulatory death donor livers (22.8% NMP vs 44.6% SCS) and in organs in the highest risk quartile by donor risk (19.2% NMP vs 33.3% SCS). The incidence of acute cardiovascular decompensation at organ reperfusion, “postreperfusion syndrome,” as a secondary outcome was reduced in the NMP arm (5.9% vs 14.6%). Conclusions: NMP did not lower EAD, perhaps related to the inclusion of lower-risk liver donors, as higher-risk donor livers seemed to benefit more. The technology is safe in standard organ recovery and seems to have the greatest benefit for marginal donors.
Artificial intelligence‐based reticulin proportionate area – a novel histological outcome predictor in hepatocellular carcinoma
Patil, Ameya , Salvatori, Rebecca , Smith, Lindsey , Jenkins, Sarah M. , Hartley, Christopher , Moreira, Roger K. , Cannon, Andrew , Hartley, Christopher P., Hartley, Christopher P , Graham, Rondell P.

Mayo Clinic

Histopathology | June 30, 2023 | Volume: 83 | Issue: 4 | Pages: 512-525

10.1111/his.15001 | PMID 37387193 Get It

Aims Reticulin stain is used routinely in the histological evaluation of hepatocellular carcinoma (HCC). The goal of this study was to assess whether the histological reticulin proportionate area (RPA) in HCCs predicts tumour‐related outcomes. Methods and results We developed and validated a supervised artificial intelligence (AI) model that utilises a cloud‐based, deep‐learning AI platform (Aiforia Technologies, Helsinki, Finland) to specifically recognise and quantify the reticulin framework in normal livers and HCCs using routine reticulin staining. We applied this reticulin AI model to a cohort of consecutive HCC cases from patients undergoing curative resection between 2005 and 2015. A total of 101 HCC resections were included (median age = 68 years, 64 males, median follow‐up time = 49.9 months). AI model RPA reduction of > 50% (compared to normal liver tissue) was predictive of metastasis [hazard ratio (HR) = 3.76, P = 0.004, disease‐free survival (DFS, HR = 2.48, P < 0.001) and overall survival (OS), HR = 2.80, P = 0.001]. In a Cox regression model, which included clinical and pathological variables, RPA decrease was an independent predictor of DFS and OS and the only independent predictor of metastasis. Similar results were found in the moderately differentiated HCC subgroup (WHO grade 2), in which reticulin quantitative analysis was an independent predictor of metastasis, DFS and OS. Conclusion Our data indicate that decreased RPA is a strong predictor of various HCC‐related outcomes, including within the moderately differentiated subgroup. Reticulin, therefore, may represent a novel and important prognostic HCC marker, to be further explored and validated.
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
Coveler, Andrew L. , Smith, David C. , Curti, Brendan D. , Goel, Sanjay , Kuzel, Timothy M. , Rixe, Olivier , Bajor, David L. , Gutierrez, Martin , Lee, Hun Ju , Heath, Elisabeth I. , Thompson, John A. , Ansari, Sahar , Jacquemont, Céline, Topletz‐Erickson, Ariel R. , Zhou, Peigen , Curti, Brendan , Goel, Sanjay , Phillips, Tycel , Mehta, Amitkumar , Markovic, Svetomir N. , Gajewski, Thomas Frank , Gopal, Ajay K. , Caimi, Paolo F. , Ansari, Sahar, Schmitt, Michael W. , Grilley‐Olson, Juneko E.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 29, 2023 | Volume: 11 | Issue: 6 | Pages: e005584

10.1136/jitc-2022-005584 | PMID 37385724 Get It

Background SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody that activates CD40, an immune-activating tumor necrosis factor receptor superfamily member. SEA-CD40 exhibits enhanced binding to activating FcγRIIIa, possibly enabling greater immune stimulation than other CD40 agonists. A first-in-human phase 1 trial was conducted to examine safety, pharmacokinetics, and pharmacodynamics of SEA-CD40 monotherapy in patients with advanced solid tumors and lymphoma. Methods SEA-CD40 was administered intravenously to patients with solid tumors or lymphoma in 21-day cycles with standard 3+3 dose escalation at 0.6, 3, 10, 30, 45, and 60 µg/kg. An intensified dosing regimen was also studied. The primary objectives of the study were to evaluate the safety and tolerability and identify the maximum tolerated dose of SEA-CD40. Secondary objectives included evaluation of the pharmacokinetic parameters, antitherapeutic antibodies, pharmacodynamic effects and biomarker response, and antitumor activity. Results A total of 67 patients received SEA-CD40 including 56 patients with solid tumors and 11 patients with lymphoma. A manageable safety profile was observed, with predominant adverse events of infusion/hypersensitivity reactions (IHRs) reported in 73% of patients. IHRs were primarily ≤grade 2 with an incidence associated with infusion rate. To mitigate IHRs, a standardized infusion approach was implemented with routine premedication and a slowed infusion rate. SEA-CD40 infusion resulted in potent immune activation, illustrated by dose dependent cytokine induction with associated activation and trafficking of innate and adaptive immune cells. Results suggested that doses of 10–30 µg/kg may result in optimal immune activation. SEA-CD40 monotherapy exhibited evidence of antitumor activity, with a partial response in a patient with basal cell carcinoma and a complete response in a patient with follicular lymphoma. Conclusions SEA-CD40 was tolerable as monotherapy and induced potent dose dependent immune cell activation and trafficking consistent with immune activation. Evidence of monotherapy antitumor activity was observed in patients with solid tumors and lymphoma. Further evaluation of SEA-CD40 is warranted, potentially as a component of a combination regimen. Trial registration number NCT02376699.
Tenascin‐R Autoimmunity: Isolated Tremor Reversed with Immunotherapy
Yang, Binxia , McKeon, Andrew , Ahlskog, J. Eric , Tipton, Philip W. , Guo, Yong , Lucchinetti, Claudia F. , Pittock, Sean J. , Ζεκερίδου, Αναστασία , Brown, Andrew E. , Pittock, S J , Brown, Andrew , McKeon, Andrew , Tipton, Philip W , Lucchinetti, Claudia F , Zekeridou, Anastasia , Yang, Binxia , Brown, Andrew D.

Mayo Clinic

Annals of Neurology | June 28, 2023 | Volume: 94 | Issue: 3 | Pages: 502-507

10.1002/ana.26730 | PMID 37370243 Get It

Autoimmune movement disorders are increasingly recognized, but isolated tremor is extremely rare. We describe a 70‐year‐old male with rapidly progressive, severe postural and intention tremor and weight loss. His cerebrospinal fluid was inflammatory and harbored a neural tissue‐restricted antibody. The autoantigen was identified by immunoprecipitation and mass spectrometry and confirmed by antigen‐specific assays to be specific for tenascin‐R. He was investigated for cancer and diagnosed with follicular lymphoma that expressed tenascin‐R suggesting a paraneoplastic origin; cancer treatment and immunotherapy led to complete recovery. With this individualized patient approach and antibody discovery, we expand the spectrum of antibodies accompanying autoimmune hyperkinetic movement disorders. ANN NEUROL 2023;94:502–507
Marginal Ulcers after Roux-en-Y Gastric Bypass: Etiology, Diagnosis, and Management
Salame, Marita , Belluzzi, Amanda, Al-Kordi, Mohammad, Jawhar, Noura , Storm, Andrew C. , Dayyeh, Barham K. Abu , Ghanem, Omar M.

Mayo Clinic

Journal of Clinical Medicine | June 28, 2023 | Volume: 12 | Issue: 13 | Pages: 4336

10.3390/jcm12134336 | PMID 37445371 Get It

Marginal ulcer (MU) is a potential complication following Roux-en-Y gastric bypass (RYGB), with a mean prevalence of 4.6%. Early identification and prompt intervention are crucial to mitigating further complications. The pathophysiology of MU is complex and involves multiple factors, including smoking, Helicobacter pylori infection, non-steroidal anti-inflammatory drug (NSAID) use, and larger pouch size. Patients with MU may experience acute or chronic abdominal pain. Rarely, they may present with a complication from the ulceration, such as bleeding, perforation, or strictures. Following diagnosis by endoscopy, management of MU typically involves modification of risk factors and medical therapy focused on proton pump inhibitors. In case of complicated ulcers, surgical intervention is often required for the repair of the perforation or resection of the stricture. For recurrent or recalcitrant ulcers, endoscopic coverage of the ulcer bed, resection of the anastomosis, and abdominal or thoracoscopic truncal vagotomy may be considered. This review aims at providing an overview of the etiology, diagnosis, and management of MU after RYGB.